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A B S T R A C T 
Introduction: Colorectal cancer risk stratification traditionally focuses on tumor node metastasis staging. 
Seemingly equivalent tumors can differ unpredictably in prognosis; more sophisticated quantification and 
stratification methods are required to identify tumors with a high likelihood of becoming metastatic. 
Hypoxia (low oxygen concentration) is associated with aggressive phenotypes and poor prognosis. Hypoxia 
is associated with treatment resistance consequently there is an unmet clinical requirement to develop 
personalised treatment based on hypoxia. Positron emission tomography/computed tomography (PET/CT) 
imaging can non-invasively detect hypoxic tumors. [18F]Fluoroazomycin arabinoside ([18F]FAZA) is a 
leading hypoxia PET/CT radiotracer, and uptake is associated with lower disease free survival. Case 
Report: A 78-year-old man, diagnosed with a localised colorectal cancer, underwent [18F]FAZA PET/CT 
imaging pre-operatively. This confirmed hypoxic regions in the tumor with correlation demonstrated with 
carbonic anhydrase IX (CAIX) immunohistochemistry (IHC). He underwent a right hemicolectomy. The 
pathological staging for his colorectal cancer predicted a good outcome; thus, he did not receive adjuvant 
chemotherapy. The patient subsequently developed early metastatic disease with two lung metastases, which 
were resected by thoracotomy and wedge resection. He continues on follow up at present with no evidence 
of recurrent disease. Conclusion: Hypoxia can be an important marker in colorectal cancer when 
determining risk and prognosis. We present evidence of clinical correlation of FAZA uptake and CAIX IHC 
in colorectal cancer, a key aspect in FAZA tracer validation. PET/CT potentially provides a specific tool for 
stratification for hypoxia-related treatment modification and development of hypoxia biomarkers. 
                                                  © 2020 Kirsten Laws. Published by Nature Library Ltd. All rights reserved  
1. Introduction 
 
Risk stratification for colorectal cancer has traditionally used the tumor 
node metastasis (TNM) staging system. Seemingly equivalent tumors 
can differ unpredictably in prognosis and treatment response; more 
sophisticated quantification and stratification methods are required to 
identify tumors with a high likelihood of progressing or becoming 
metastatic. The role of non-anatomical factors is becoming more 
prominent, including lymphocytic infiltration, venous invasion, tumor 
deposits, budding, circumferential margin status, distribution of nodal 
metastases and genetic characteristics [1]. Four transcriptional 
consensus molecular subtypes (CMS) have been proposed, each 
associated with distinct histopathological features including 
microsatellite instability (MSI) status, CpG island methylator phenotype, 
somatic copy number alterations, BRAF mutations, KRAS mutations, 
and immune infiltration [2]. 
 
Hypoxia (low oxygen concentration) is an additional characteristic for 
stratification because it is associated with treatment resistance, 
aggressive phenotypes and poor prognosis in most solid tumor types. By 
using radioactive molecules that are selectively retained in hypoxic cells, 
positron emission tomography/computed tomography (PET/CT) 
imaging can non-invasively detect hypoxic regions. PET/CT can 
visualize the heterogeneous nature of O2 levels across the entire tumor, 
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quantify the hypoxic region(s), be utilised at multiple time points, and 
permit the effect of therapy on oxygenation to be assessed. Accordingly, 
its potential application in assisting the development of treatment 
strategies such as radiotherapy dose painting and hypoxia-targeted 
pharmacotherapies is being precisely investigated. Equally, it has the 
potential to help identify hypoxia gene expression signatures that may 
aid the assessment of prognosis or development of tailored therapeutic 
options. As yet, there is limited research into the use of hypoxia PET/CT 
in colorectal cancer, with more widespread development in head and 
neck (H&N), lung and glioblastoma tumors [3].  Given the documented 
treatment resistance related to hypoxia, there is a clear and unmet clinical 
requirement to develop a personalised treatment plan based on hypoxia.  
 
 [18F]Fluoroazomycin arabinoside ([18F]FAZA) is one of the leading 
hypoxia PET/CT radiotracers [3]. [18F]FAZA has been studied in H&N 
and non-small cell lung cancer (NSCLC) patients, with clear uptake seen 
[4]. Increased uptake in H&N patients is strongly associated with lower 
disease-free survival [5]. [18F]FAZA has potential advantages over 
another leading hypoxic tracer, [18F]fluoromisonidazole ([18F]FMISO), 
due to lower background signal and shorter time (1-2h) required between 
injection and imaging. One study has previously demonstrated feasibility 
for [18F]FAZA uptake in colorectal cancer [6].  A key aspect of tracer 
validation is the correlation of hypoxia PET/CT data with 
immunohistochemistry (IHC) hypoxia assessment. Correlation between 
[18F]FMISO and standard hypoxia IHC markers such as Hypoxia 
Inducible Factor 1a (HIF1α) expression in H&N patients has been 
demonstrated [7, 8]. However, these results have not yet been 
convincingly replicated with [18F]FAZA PET/CT in the clinical setting 
[9, 10].  
 
We present a case where anatomical and pathological staging predicted 
a good outcome. As part of a pilot study, the patient had pre-operative 
[18F]FAZA PET/CT imaging, which suggested hypoxic regions in the 
tumor, confirmed with carbonic anhydrase IX (CAIX) staining on IHC. 
The patient subsequently developed early metastatic disease, suggestive 
of a more aggressive disease process than anticipated from the initial 
favourable pathology. This case highlights that hypoxia can be an 
important marker in colorectal cancer when determining risk and 
prognosis. Furthermore, the correlation of FAZA PET/CT uptake with 
hypoxia IHC markers such as CAIX can be demonstrated in a case of 
colorectal cancer. Hypoxia PET/CT potentially provides a specific tool 
for stratification for hypoxia-related treatment modification.  
 
2. Case Report 
 
A 78-year-old male presented with fatigue and dizziness, postural 
hypotension, diarrhoea, and bleeding per rectum (PR), associated with 
iron deficiency anaemia. He had no other significant history, including 
no altered bowel habit, pain, dysphagia or vomiting. Past medical history 
included hypertension and diet-controlled type 2 diabetes mellitus. There 
was no significant family history, and previous colorectal screening was 
negative. He was fully independent of activities of daily living with 
World Health Organisation (WHO) performance status 0.  He was 
initially reviewed in the clinic, and an outpatient colonoscopy and upper 
gastrointestinal endoscopy (UGIE) was arranged. There were no 
significant findings on initial examination. His routine blood tests 
confirmed iron deficiency anaemia with ferritin 12.6. However, he was 
subsequently admitted with postural hypotension, diarrhoea and fresh 
per rectum (PR) bleeding, associated with anaemia. This was managed 













FIGURE 1: [18F]FAZA uptake in colorectal primary.  
Image demonstrating [18F]FAZA  uptake (purple) within colorectal 
primary (white outline), consistent with a hypoxic tumor. Tumor SUV 
max was 2.65, with a T:M ratio of 1.80 measured from baseline of 
skeletal muscle (white circle) and baseline uptake of adjacent bowel. 
 
A CT staging scan confirmed a caecal mass, measuring 9 x 7 x 7.5cm 
with multiple enlarged local lymph nodes but no evidence of distant 
metastases.  He subsequently underwent a colonoscopy, which 
confirmed a caecal tumor, and biopsy confirmed high-grade dysplasia 
with features suspicious of adenocarcinoma. Given the extent of disease 
on imaging and colonoscopy, the gentleman was reviewed and 
considered for a right hemicolectomy. As part of a pilot clinical study, 
the day prior to surgery, he underwent a [18F]FAZA  PET/CT scan, 
which confirmed radiotracer uptake within the primary tumor, 
suggesting the tumor contained hypoxic regions. Images were examined 
using the PBAS PET image analysis suite (PMOD Technologies, Zurich, 
CH). Regions of interest were defined by a trained Radiologist and 
analysed in conjunction with the PET uptake data for the creation of 
time-activity curves and uptake values. Regions were defined around the 
tumor, an adjacent area of normal bowel and an area of skeletal muscle. 
The tumor maximum standardised uptake value (SUV) was 2.65, with a 
tumor:muscle (T:M) ratio of 1.80 (Figure 1).  The definition of hypoxia 
is generally accepted in the literature as tumor:background ratio of ≥ 1.4 
[3].  
 
The patient underwent a right hemicolectomy, with the tumor clearly 
identified and resection margins macroscopically clear. Pathological 
examination of the formalin-fixed specimen confirmed a large 65mm 
polypoidal mass within the caecum, a moderately differentiated 
adenocarcinoma, invading through the muscularis propria, with no 
involved lymph nodes identified in an examination of 29 nodes and no 
extramural venous invasion. The final pathology was Dukes B, pT3 pN0, 
V0 with complete resection (R0). Additional biomarker profile 
demonstrated a Gly13Asp KRAS mutation, BRAF wild type and MSS 
stable. Immunohistochemistry (IHC) analysis of the tumor samples for 
the intrinsic hypoxic marker carbonic anhydrase nine (CAIX) [11], 
demonstrated focal positivity, confirming the hypoxic nature of the 
tumor identified on FAZA PET/CT (Figure 2). The patient was placed 
on routine follow up with no requirement for adjuvant chemotherapy. 
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FIGURE 2: Colorectal tumor immunohistochemistry demonstrates 
hypoxia.  
IHC analysis of the primary tumor demonstrating patchy positivity 
(brown) and confirming the hypoxic nature of the tumor. IHC for CAIX 




























FIGURE 3: Lung metastasis immunohistochemistry demonstrates 
hypoxia. A) Example of Haematoxylin and Eosin (H&E) Stained 
Section of lung metastasis demonstrating patchy necrosis. B) Example 
of patchy positivity (brown) of CAIX staining for lung metastasis. 
 
One year after his initial surgery, a routine follow-up CT scan, 
unfortunately, demonstrated 2 new lesions within the right lung (RUL 
and RML), likely to represent metastatic disease. The two lung lesions 
were confirmed to be avid on [18F]fluorodeoxyglucose (18F-FDG) 
PET/CT scan, but there was no evidence of local recurrence or other 
metastatic disease. He, therefore, underwent a right thoracotomy and 
wedge resection of the two lung nodules. In both lesions, histology 
confirmed a multinodular deposit of enteric pattern adenocarcinoma, in 
keeping with metastatic disease from the patient's previous caecal 
adenocarcinoma. Histology confirmed areas of necrosis and patchy 
CAIX positivity (Figures 3A & 3B). The gentleman remains on follow 




Colorectal cancer prognostication traditionally arises from the TNM 
staging system, with additional risk factors assessed including 
extramural venous invasion, to ascertain if a patient requires adjuvant 
chemotherapy [1]. However, it is apparent that the outcome of patients 
may vary considerably within the same TNM stage classification. This 
was clearly demonstrated in relation to this case, where the patient 
developed metastases unexpectedly given the original relatively low risk 
predicted by the histopathological assessment. These variations and 
unexpected results in certain patients can be explained by the widespread 
diversity evident at a molecular level. Consequently, further 
stratification of tumors is required; the proposed consensus molecular 
subtypes consist of a combination of molecular subtyping and specific 
biomarkers that can provide additional prognostic information above the 
traditional TNM staging [2]. Further assessments could potentially 
identify subpopulations of patients that would benefit from additional 
treatment despite favourable TNM classification. The pertinence of this 
was clearly demonstrated in this case, where no additional treatment was 
deemed to be required post operatively based on the initial favourable 
TNM pathology.  
 
Hypoxia is an alternative biomarker shown to be a potential marker for 
prognosis in colorectal cancer. Hypoxia inducible factor 1 alpha (HIF1a) 
induction is established as the key driver allowing cells to adapt to 
hypoxia as reflected by subsequent downstream expression of genes 
involved in angiogenesis, glycolysis and cell survival. In colorectal 
cancer, a large prospective cohort study has evaluated HIF1a expression 
in relation to prognosis [11]. The study demonstrated that HIF1a 
expression, as determined by cytoplasmic positivity on 
immunohistochemistry, was independently associated with poor 
prognosis [11]. A subsequent meta-analysis of 23 studies also 
demonstrated a strong association between HIF1a overexpression and 
increased mortality risk; both overall survival and disease-free survival 
correlated with HIF1a expression using nuclear or cytoplasmic staining 
[12]. Despite the evidence of association with prognosis and outcomes, 
assessment of hypoxia and HIF is not yet included in the routine 
assessment of colorectal cancer patients and is not considered in the 
colorectal consensus molecular subtypes. One potential explanation for 
this is the variability of HIF expression and the reliability of its 
assessment by immunohistochemistry; not all studies identify a positive 
correlation, with a recent retrospective analysis of 186 patients 
demonstrating no significant correlation between HIF1a, CAIX and 
survival outcomes [13].   
 
An alternative method of assessing hypoxia involves PET imaging using 
hypoxia selective radiotracers such as [18F ]FMISO or [18F]FAZA. These 
have the benefit of assessing the entire tumor, being non-invasive, 
permitting evaluating of hypoxia at multiple time points and 
distinguishing between acute and chronic hypoxia. There is minimal 
clinical data in the literature regarding hypoxia PET/CT in colorectal 
cancer, with the majority of previous studies focusing on H&N, lung, 
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and GBM [3], with only one study demonstrating the feasibility of 
[18F]FAZA as a hypoxia imaging marker in colorectal cancer [6]. 
Furthermore, although a correlation of FAZA uptake with IHC has been 
demonstrated previously in the preclinical setting, it has yet to be 
convincingly demonstrated in the clinical setting [9, 14].  One study has 
demonstrated CAIX correlation with FAZA in non-small cell lung 
cancer (NSCLC) in one case [10]. We add to the literature by presenting 
the first case of colorectal cancer demonstrating this correlation.  
 
The correlation of FAZA uptake with immunohistochemistry hypoxia 
markers is a crucial step in tracer validation as a hypoxia biomarker. 
Mapelli et al. demonstrated a positive correlation in one NSCLC case, 
but two NSCLC cases without FAZA uptake also demonstrated CAIX 
positivity [10]. Possible explanations for this include the difference 
between acute and chronic hypoxia. Given the limited correlations of this 
in the current literature, further work is required in this area to fully 
validate FAZA as a reliable hypoxia PET/CT tracer in the clinical 




Assessment of tumor hypoxia by PET/CT is a promising biomarker; 
there is a clear correlation between hypoxia PET/CT uptake and poorer 
prognosis. This case demonstrates how patients might benefit from the 
recognition of hypoxia in otherwise good prognostic tumors.  The 
hypoxic nature of the patient’s tumor could potentially explain the 
discrepancy in the original favourable low-risk pathology and the 
unexpected development of metastases, highlighting the use of PET/CT 
as a specific tool for the stratification for hypoxia-related treatment 
modification. This case provides the first clinical correlation of FAZA 
uptake and CAIX IHC in a colorectal cancer case, a key aspect in FAZA 
tracer validation. Further research is required to ensure standardisation 
of the definition of hypoxia, the development of standard imaging 
protocols, the reproducibility of these imaging biomarkers and their 
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Fully informed consent was obtained from the patient to take part in the 
study. Fully informed consent was also obtained for publication in the 
form of this case report.  
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[18F]FAZA: [18F]Fluoroazomycin Arabinoside 
[18F]FMISO: [18F]Fluoromisonidazole  
[18F]DG: [18F]Fluorodeoxyglucose  
CAIX: Carbonic Anhydrase Nine 
CMS: Consensus Molecular Subtypes 
GBM: Glioblastoma 
H&E: Haematoxylin and Eosin 
H&N: Head and Neck Cancers 
HIF1a: Hypoxia Inducible Factor 1 alpha 
IHC: Immunohistochemistry 
MSI: Microsatellite Instability 
NSCLC: Non-Small Cell Lung Cancer 
PET/CT: Positron Emission Tomography / Computed Tomography 
PR: Per Rectum 
RCC: Red Cell Concentrates 
RML: Right Lung, Middle Lobe 
RUL: Right Lung, Upper Lobe  
SUV: Standardised Uptake Value 
T:B: Tumor to Background ratio 
T:M: Tumor to Muscle Ratio 
TNM: Tumor Node Metastasis Staging 
UGIE: Upper Gastrointestinal Endoscopy 
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